Gamida Cell
Gamida Cell Reports Full Year 2022 Financial Results and Provides Company Update
- Form
- 8-K
- Filed
- Period
- Importance
- Major
- Accession
- 0001213900-23-022951
- Document
- 8-K
- Exhibit 99.1
- Press release, dated March 27, 2023
- Reports quarterly results (2.02)
- Announces exit or restructuring costs (2.05)
Not explained yet; the original is on EDGAR.
Similar companies
Same SIC code (2836) and public float not reported.
- Adaptimmune Therapeutics ADAP
- Adverum Biotechnologies ADVM
- AgomAb Therapeutics AGMB
- Alvotech ALVO
- Argenx ARGX
